PMC5574659_01
MRI of case one (a) before imatinib (axial section) (b) before imatinib (coronal section) (c) after 3 months imatinib (d) after 6 months imatinib.
can-11-760fig1.jpg
PMC5574659_01_can-11-760fig1.jpg
figure1
Clinical oncologists started Imatinib (Gleevec ) at 400 mg daily dose for three months with good radiological response, the lesion downsized to 1.5 cm in maximum diameter (Figure 1).
Case one (a) white thickened patch at the site of the tumour (b) Resection of the residual lesion.
can-11-760fig2.jpg
PMC5574659_01_can-11-760fig2.jpg
figure2
The patient was positioned in the right lateral decubitus and wide local excision using TEO platform was done, followed by primary suturing with V-Loc  suture (Covidien, MA, USA) (Figure 2).
PMC5574659_02
MRI of case two (a) axial section showing large tumour in the left anterolateral wall of the anal canal (b) Coronal section showing no extraluminal extension (c) T1-weighted and (d) T2-weighted sagittal views showing the tumour relation to the posterior vaginal wall.
can-11-760fig3.jpg
PMC5574659_02_can-11-760fig3.jpg
figure3
Pelvic MRI reported intraluminal mass in the rectum 4.5 cm, infiltrating the left lateral rectal wall (Figure 3).
Resection of case two (a) dissection of friable tumour (b) tumour dissected completely from the left side with intact musculosa (c) cutting the remaining attachment with Harmonic scalpel.
can-11-760fig4.jpg
PMC5574659_02_can-11-760fig4.jpg
figure4
After complete resection, further separate safety margins from the edges and depth of the cavity were sent for histopathological examination (Figure 4).
Pathology specimens of case two (a) shows interlacing bundles of spindle cells (H&E staining, 100x) (b) shows interlacing bundles of spindle cells (H&E staining, 400x) (c) shows positive membranous reaction (CD117 immunostaining, 400x) (d) shows positive membranous reaction (DOG-1 immunostaining, 400x).
can-11-760fig5.jpg
PMC5574659_02_can-11-760fig5.jpg
figure5
Pathology revealed a low-risk GIST with microscopic infiltration of left margin confirmed by immunostain (Figure 5).